Last reviewed · How we verify
Lazertinib group
At a glance
| Generic name | Lazertinib group |
|---|---|
| Also known as | Leclaza |
| Sponsor | Se-Hoon Lee |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (PHASE1)
- Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients (PHASE2)
- A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937) (PHASE1)
- Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers. (PHASE1)
- Impact of Lazertinib Dose Modification on Effectiveness and Safety
- Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
- The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lazertinib group CI brief — competitive landscape report
- Lazertinib group updates RSS · CI watch RSS
- Se-Hoon Lee portfolio CI